How can we help?

Contact
Invest & set up an operation in Costa Rica »

Talk to the experts in each specific sector of interest, meet key service providers, request information and benchmarks and much more.

Write a message here
Feedback
Feedback on CINDE services »

Help us become better every day. Share you suggestions or any complaints about CINDE´s services to our quality assurance department.

Keep in touch

  • Linkedin
  • YouTube
  • Email
CINDE New York

100 Park Avenue, 16th Floor
New York, NY 10017

CINDE Costa Rica

Plaza Roble Los Balcones, 4th Floor.
Escazu, San Jose, Costa Rica

TOLL FREE NUMBER FROM THE USA: 1-877-992-4633

Essential Info

  • Intro
  • INVESTMENT SECTOR
  • Documents
  • DOWNLOAD

Download key information tailored to your investment interest, at no cost.

  • Fast
  • Convenient
  • Reliable

The final essential INFO will include:

Key information on Costa Ricas education quality and trends, labor pool and regulations, free trade zone and investment incentives, economic indicators, suppliers and vendors, life in Costa Rica and much more.

Choose one of the following investment sectors:

Telling us your business’ sector allows us to prepare more accurate data based on your request.

Choose the documents you're interested in obtaining

This is a list of files generated based on your Investment Sector choice

You’re all set!

Your customised essential INFO is getting ready...

Check your email You will receive an email in a few moments with the files we have prepared for you!

Remember, you can run this wizard as many times as you want!

LOGIN

Reset your password

  • We will send you instructions to reset your password

  • Your email is not in our records

I want to register!

Register

How do you want to create your account?

Register today and stay on top of the latest from Costa Rica.

  • Access and download key information on benchmarks, data and statistics from the country.
  • Receive newsletters from the latest economic and investment related initiatives.
  • Get news alerts on key country developments.
  • And much more.

Please fill the following information to create your account

Go Back

Please check the form is complete.

Thank you for registering with CINDE

Your account has been succesfully created.

If you have any problems, please:

Contact us

My Profile

Your health and safety is our top priority. We're operating 100% remotely.

LEARN MORE »Learn how CINDE is responding to COVID-19

Check out Costa Rica's Response Guidelines to Covid-19 and learn how to achieve business continuity in our country

LEARN MORE »

News Room

Feel connected with


our essence

Get the latest updates from our
events, press releases and more!

News

Viracor Eurofins Launches Coronavirus SARS-CoV-2 RT-PCR Test with Same Day Results (12-18 Hours)

MARCH 12th 2020

Article and picture originally from Viracor Eurofins 
Mar 10, 2020, 15:41 ET    

LEE'S SUMMIT, Mo., March 10, 2020/PRNewswire/ -- Viracor Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will start testing specimens for Coronavirus SARS-CoV-2 RT-PCR as of March 13, 2020.  The new test utilizes real-time reverse-transcriptase polymerase chain reaction (RT-PCR) technology and detects the new coronavirus (SARS-CoV-2).  Viracor's qualitative Coronavirus SARS-CoV-2 RT-PCR assay will be tested on BAL, NP swab, Nasal Swab, NP Wash, and Nasal Wash specimen types.  Healthcare providers can expect results the same day, 12-18 hours from receipt of specimen.

Patients with suspected cases of COVID-19 should consult with a physician regarding ways to provide a specimen for testing by Viracor.  Various types of respiratory and serological specimens can be used to detect latent, acute and retrospective clinical cases associated with COVID-19.

Given the growing impact of the 2019 novel coronavirus, Viracor has been working to deliver a diagnostic solution to help combat this public health emergency.  Viracor can now provide an accurate, fast test for measuring the presence of SARS-CoV-2 in patients suspected of having COVID-19.

About Viracor Eurofins
Viracor Eurofins is a leader in specialty clinical diagnostics with over 35 years and 3000 test offerings in infectious diseases, transplantation, immunology, and allergy, to aid diagnosis, treatment, and monitoring. Viracor Eurofins is committed to helping medical professionals, transplant teams, reference laboratories, and biopharmaceutical companies get results faster when it matters most. For more information about the company and the new tests, please visit https://bit.ly/2vPsab7

As a member of Eurofins Scientific, a global leader in laboratory services for specialty clinical diagnostics, discovery pharmacology and supporting clinical studies, Viracor serves many leading biopharmaceutical companies and a wide range of clinical and academic customers in the U.S.

Viracor is a 100 percent subsidiary of Eurofins Scientific (EUFI.PA), the global leader in bio-analytical testing, and one of the world leaders in genomic services. For more information, please visit https://www.eurofins.com/ and https://www.viracor-eurofins.com/.

About Eurofins - A global leader in bio-analysis
Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialized by end-client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
SOURCE Viracor Eurofins

Related Links